In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months.
Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351
Back us on Patreon! www.patreon.com/plenarysession
Fler avsnitt av Plenary Session
Visa alla avsnitt av Plenary SessionPlenary Session med Vinay Prasad, MD MPH finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
